Fibrinolysis activation occurs almost universally following severe injury.
1 Physiological fibrinolysis is a proportionate response to increased fibrin generation following tissue trauma, 2 whereas excessive or systemic fibrinolytic activation is inappropriate and potentially lethal. Acute traumatic coagulopathy (ATC) is an early and endogenous hemostatic abnormality of which global hypocoagulation, systemic hyperfibrinolysis, 3, 4 early fibrinogen depletion, and platelet dysfunction 5 are key components. ATC is triggered by massive tissue injury in conjunction with hypoperfusion (shock) in the early phase after major trauma. 3 Hyperfibrinolysis is defined by disproportionately increased fibrinolytic activity with respect to fibrin formation, 6 and is associated with poor clot integrity, excessive bleeding, and worse coagulopathy, in addition to increased morbidity and mortality.
7
Controversy currently exists over patient selection for antifibrinolytic therapy 8 and is a reflection of our limited understanding of both the mechanism and dynamics of fibrinolytic activation after traumatic injury. Hyperfibrinolysis in trauma has yet to be properly defined with many different arbitrary definitions used in the literature (►Table 1). Sensitive diagnostics for a rapid and current assessment of the fibrinolytic system are lacking 2 despite the increasing use of viscoelastic hemostatic assays (VHA) (e.g., rotational thromboelastometry (ROTEM; Tem International GmbH, Munich, Germany) and thromboelastography (TEG; Haemonetics, Braintree) to define Keywords ► trauma ► fibrinolysis ► hemorrhage ► coagulopathy ► tranexamic acid
Abstract
Fibrinolysis activation occurs almost universally after severe trauma. Systemic hyperfibrinolysis is a key component of acute traumatic coagulopathy and associated with poor clinical outcomes, although controversy exists over optimal treatment strategies.
The mechanistic drivers and dynamics of fibrinolytic activation in response to injury and trauma resuscitation are currently unclear. Furthermore, therapeutic triggers are compounded by the lack of a sensitive and rapid diagnostic tool, with discrepancy between hyperfibrinolysis diagnosed by viscoelastic hemostatic assays versus biomarkers for fibrinolysis. Rotational thromboelastometry and thromboelastography appear capable of detecting the severest forms of hyperfibrinolysis but are relatively insensitive to moderate, yet clinically significant fibrinolytic activation. Rapid evaluation of the current status of the fibrinolytic system remains a challenge and therefore the decision whether to administer an antifibrinolytic agent should be based on available evidence from clinical trials. In line with current European guidelines, we recommend that all bleeding trauma patients, and in particular, severely injured patients with evidence of hemorrhagic shock, should receive early empiric tranexamic acid. This review explains our current knowledge of the pathophysiological pathways which induce hyperfibrinolysis in trauma hemorrhage, evaluates the available diagnostic modalities, and describes current treatment strategies.
fibrinolytic activation states. Correlation of lysis parameters with laboratory gold standards of fibrinolysis, for example, plasmin-α2-antiplasmin (PAP) complex (PAP) levels has proven difficult to interpret, and therefore, the clinical sequela of acute hyperfibrinolysis and/or early hypofibrinolysis has yet to be accurately described. In particular, the impact of a highly activated (or inhibited) fibrinolytic system on bleeding risk, organ failure, and thrombotic complications is unclear. Understanding the drivers of trauma-induced fibrinolysis, the temporal relationship to injury and resuscitation, as well as optimal treatment strategies are priorities for the trauma research community. The purpose of this review is to explain our current knowledge of the pathophysiological pathways which induce hyperfibrinolysis in trauma hemorrhage, evaluate the available diagnostic modalities, and describe current treatment strategies.
Regulation of Fibrinolysis
The coagulation and fibrinolytic systems are both activated following trauma and exist in a dynamic equilibrium.
1,9
Plasmin degrades fibrin and prevents propagation of the clot distant to the site of injury. Plasminogen may be activated either by tissue-type or urinary-type plasminogen activators (tPA and uPA, respectively) or by the contact pathway. tPA is a serine protease produced and secreted primarily by precapillary arteriole and postcapillary venule endothelial cells [10] [11] [12] and is the primary plasminogen activator in the vasculature. In response to vascular injury or the presence of thrombin, additional stores of tPA from endothelial Weibel-Palade bodies 13 and possibly by poorly characterized other small storage granules 14 are released.
15
Fibrinolytic activation is tightly controlled by plasminogen activator inhibitor 1 (PAI-1) which principally inhibits tPA and alpha-2 antiplasmin (α2AP) which inhibits plasmin. PAI-1 is found within two distinct pools within the bloodplasma and platelets. 16 Circulating levels of PAI-1 are relatively low in comparison to the rich source within platelet α-granules. 16 Platelet-rich thrombi are resistant to tPA-mediated fibrinolysis 17 ; however, platelet contribution to plasma levels of PAI-1 and the degree to which platelets modulate trauma-induced hyperfibrinolysis are uncertain. Although initial studies suggested that only 10% of platelet PAI-1 was in an active configuration, 18-20 subsequent research has 
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Characterization of the antifibrinolytic capacity of platelets and the efficacy of platelet transfusions on clot stability following trauma are therefore a research priority. Importantly, recent studies have indicated platelets also contain profibrinolytic properties (outlined in the article by Whyte et al), which should be considered in such studies.
30

Fibrinolytic System in Traumatic Coagulopathy
ATC is an endogenous process, driven by the combination of endothelial hypoperfusion and tissue injury, with hyperfibrinolysis, hypocoagulation, increased thrombin generation, and early fibrinogen depletion identified as key components. 3, 31 Present in up to 25% of trauma patients, ATC occurs in the first hour after injury, before significant fluid resuscitation or hemodilution has occurred. 32, 33 During resuscitation of the bleeding trauma patient, ATC is compounded by ongoing blood loss and treatment strategies which utilize hypocoagulable fluids, for example, crystalloids, with ensuing hemodilution, hypothermia, and acidemia development contributing to a global failure of the coagulation system. Trauma-induced coagulopathy (TIC) 34 describes collectively the innate component of ATC and all subsequent coagulopathies which develop, typically iatrogenic and related to suboptimal fluid resuscitation or delayed hemorrhage control. 35 A temporal switch in coagulation status from the initial hypocoagulability of TIC to a hypercoagulable response occurs over hours to days after major trauma. 36, 37 A biphasic response has similarly been described in the fibrinolytic system 38,39 with an initial acceleration of clot lysis lasting for several hours after injury, followed by inhibition of fibrinolytic capacity lasting between 4 and 11 days.
40
Activation of the protein C (PC) pathway has been identified in both clinical human studies and experimental animal models as a potential mediator of hyperfibrinolysis in ATC. [41] [42] [43] [44] In addition to its inhibitory effect on thrombin generation, activated PC in excess binds to and neutralizes PAI-1, resulting in derepression of shock-mediated tPA release from the endothelium leading to uninhibited activation of fibrinolysis. 41, 45, 46 PAI-1 rather than TAFI appears to exert greater control over the fibrinolytic state after trauma. 1, 3 Gando et al alternatively consider traumatic coagulopathy to reflect disseminated intravascular coagulation (DIC) with a fibrinolytic phenotype, characterized by activation of the tissue factor-dependent coagulation pathway, insufficient anticoagulant mechanisms, and increased fibrinolysis. 47, 48 Primary and secondary fibrin(ogen)olysis are considered to be pathologically activated following trauma in response to shock-induced endothelial tPA release 47, 49, 50 and DIC, respectively. 48 Activation of neutrophil elastasemediated fibrinolytic pathways is additionally believed to contribute to the hyperfibrinolytic state. 51 Subsequently, it is proposed that insufficient anticoagulant mechanisms (e.g., low PC and antithrombin levels) combined with PAI-1-mediated inhibition of fibrinolysis shift the patient into DIC with a thrombotic phenotype.
47,48,52
Central to both hypotheses is the mechanism of shockinduced hyperfibrinolysis. Tissue hypoperfusion in isolation, for example, cardiac arrest, is capable of initiating hyperfibrinolysis 53, 54 and similarly increasing levels of tissue injury will initiate fibrinolysis, 
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Sympathoadrenal activation following severe trauma leads to a surge in circulating catecholamines which are hypothesized to contribute to coagulopathy and hyperfibrinolysis by means of endothelial activation and glycocalyx degradation. 55, 56 The combination of both tissue injury and hemorrhagic shock in patients suffering major trauma causes a surge in tPA release from the endothelium driving a massive fibrinolytic response.
3,52 Almost 90% of severely injured patients defined as injury severity score (ISS) > 15 have PAP levels on admission of at least twice the upper limit of normal. 1 The fibrinolytic response to trauma and shock is a dynamic process which evolves over time and may be exacerbated further by clinical interventions, for example, surgery, resuscitation. When these changes occur, and the specific drivers for any up-or downregulation in the fibrinolytic pathways are not known, in part due to limitations in our ability to measure ongoing fibrinolysis rather than markers of prior activation (e.g., PAP).
Diagnosis of Hyperfibrinolysis in Trauma
Detection of postinjury changes in the fibrinolytic system in a clinically meaningful time frame (i.e., to guide therapy) is challenging. Diagnostics currently available to quantify fibrinolysis are laboratory measures of fibrin degradation, measurement of individual proteins of the fibrinolytic system, and VHA. The euglobulin clot lysis time (ECLT) 57,58 is a validated assessment of overall fibrinolysis in vivo, however, has little clinical utility in trauma due to the prolonged assay time and loss of plasma inhibitors (i.e., antiplasmin) in the acidification process. A further limitation is that ECLT is performed on diluted platelet poor plasma rather than whole blood and it is not capable of assessing the response to antifibrinolytic therapy, since these agents are normally discarded within the supernatant during processing. 59 Excessive fibrin degradation may be indicated by raised D-dimer levels; however, elevated levels are encountered in most patients following injury 1 and are strongly correlated to injury severity. 3 Kutcher et al 60 found that patients with VHAdetectable hyperfibrinolysis have significantly higher D-dimer levels but that as a clinical marker on its own, D-dimer was not predictive of hyperfibrinolysis after adjusting for injury severity and shock. The fibrinolytic response to trauma is characterized by quantification of specific fibrinolytic proteins and complexes which are primarily measured by enzyme-linked-immunosorbent serologic assay. 1, 3, 40, 55, [61] [62] [63] Measurement of tPA and PAP complex levels in combination with fibrinolytic inhibitor levels (PAI-1, α2AP, and TAFI) enables a comprehensive albeit static assessment of the fibrinolytic system but is confined to the research setting due to the time it takes to process each assay. A functional, global assay (such as a viscoelastic test or a plasma-based clot lysis assay) may provide better overall evaluation of the status of the fibrinolytic system. 64 Any increase in fibrinolytic activation (PAP > 1,500 µg/L, twice the upper limit of normal) has been shown to be associated with a 12-fold increase in 28-day mortality and greater transfusion requirements compared with those with "normal" levels of fibrinolytic activity (PAP < 1,500 µg/L). 1 However, measurement of circulating levels of PAP or the downstream D-dimer fragment represents recent plasmin generation (and fibrinolysis) but not necessarily the extent of ongoing fibrinolysis. Development of a point-of-care test capable of rapidly quantifying the extent of fibrinolytic activation, for example, PAP or α2AP may assist in guiding therapy although in isolation would still only represent an assessment of prior fibrinolytic activity. However, in combination with a dynamic assay such as a VHA, both rapid and serial read-outs of fibrinolytic biomarker levels have the potential to better determine the degree of ongoing fibrinolysis.
Role of VHA in Trauma Hemorrhage and Diagnosis of Hyperfibrinolysis
The major advantage of VHAs over other diagnostics is near patient testing and speed, with provision of a comprehensive assessment of clot formation dynamics including fibrinolysis in whole blood. ROTEM and TEG are capable of rapidly diagnosing ATC [65] [66] [67] and are superior to conventional clotting tests (e.g., prothrombin time) in predicting the need for massive transfusion in trauma. 68 Extrapolation of the incidence and outcomes associated with hyperfibrinolysis in trauma from the literature is confounded by several methodological issues: (1) inconsistency in threshold definitions for VHA detected hyperfibrinolysis; (2) lack of standardization of VHAs with consequent laboratory-to-laboratory variation; (3) wide variation in patient populations; (4) discrepancies in sampling protocols that vary between minutes of injury to 12 hours; and (5) a lack of clarity between VHA versus biomarker diagnosed hyperfibrinolysis.
VHA detected hyperfibrinolysis is reported in 2 to 20% of trauma patients presenting to the emergency department (ED) and is associated with mortality rates up to 100% (►Table 1). found the lower threshold of 3% to be superior at diagnosing clinically relevant hyperfibrinolysis and predicting both massive transfusion and mortality. Consequently, TEG hyperfibrinolysis is now widely defined as LY30 3%.
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Is VHA Diagnosed Fibrinolysis an Accurate Reflection of the Status of the Fibrinolytic System?
VHAs accurately identify patients with the highest degree of fibrinolysis, but appears relatively insensitive at detecting lower levels of fibrinolytic activation, 1 through rapid inhibition of free tPA by PAI-1 following blood draw. 87 Using a composite measure of PAP and VHA on admission to ED, we have shown fibrinolytic activation following severe trauma to be extremely common. 1 Patients without VHA hyperfibrinolysis (ML < 15%) were categorized as "normal" fibrinolytic activity if PAP < 1,500 µg/L and "moderate" fibrinolytic activity if PAP >1,500 µg/L. Patients with PAP > 1,500 µg/L combined with VHA hyperfibrinolysis (ML > 15%) were classified as "severe." While only 5% of patients were classified as "severe," the largest proportion of patients (57%) had "moderate" fibrinolytic activation which was not detected by ROTEM. PAP levels were closely related to injury severity, with approximately 90% of patients with ISS > 15 demonstrating biomarker confirmed hyperfibrinolysis. In a similar study utilizing PAP and TEG, Cardenas et al 63 found that 45% of patients had PAP > 1,500 µg/L with an associated sixfold increase in overall mortality despite there being no evidence of hyperfibrinolysis on TEG (median LY30 1.1% (0.2-2.4) (►Table 1). 
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Differences in ROTEM and TEG methodology and the reagents used (►Table 2) alter the sensitivity to fibrinolysis across platforms and individual assays. Harr et al 88 reported that functional fibrinogen TEG and FIBTEM were comparable in their ability to detect fibrinolysis faster than the other VHA assays. KaolinTEG appears superior in its ability to detect fibrinolysis in a dose-dependent manner across various tPA concentrations, whereas RapidTEG detects lysis at high concentrations of tPA only. The more powerful clot activation required to generate faster results by RapidTEG, results in a clot more resistant to tPA-induced fibrinolysis which may result in underdiagnosis of hyperfibrinolysis. VHA and biomarkers of fibrinolysis by definition do not measure the same thing; PAP reflects prior activation of fibrinolysis in vivo whereas, VHAs quantify coagulation and to some extent fibrinolytic potential. Clarification of the status of the fibrinolytic system and therapeutic requirements of a bleeding trauma patient with grossly elevated PAP or D-dimer levels, but does not meet the diagnostic threshold for VHA hyperfibrinolysis is clearly a research imperative. The circumstances required for VHA to detect "severe" hyperfibrinolysis have yet to be confirmed. In one study, tPA levels of nearly five times normal and α2AP levels below 75% of normal were shown to be required before ROTEM hyperfibrinolysis was visualized. 1 We hypothesize that free tPA within the ROTEM cup is required to generate plasmin and that only in the presence of low antiplasmin levels is there reduced inhibition of newly formed plasmin, resulting in ROTEM-detectable hyperfibrinolysis. Platelet dysfunction may additionally influence the ability of VHA to detect hyperfibrinolysis since impairment of ADP-induced platelet activation following trauma is associated with increased sensitivity to tPA-mediated fibrinolysis. 89 Alternatively, the pattern of biomarker positive fibrinolysis with negative VHA lysis may represent prior excessive lytic activity which has rapidly reverted to normal or hypofibrinolysis during the early phase response to trauma. A further explanation may lie in the relative availability of promoters or inhibitors of fibrinolysis within the VHA with respect to thrombin generation potential since both clot strength and lysis are products of one another. At the opposite end of the spectrum, it is similarly unclear what the implications of low VHA fibrinolysis are for the trauma patient. While the upper boundary for "normal" VHA fibrinolysis (ML 15% 90 or LY30 < 3%
83
) is commonly quoted, no lower boundary has been reported and it has recently been suggested that patients with VHA hypofibrinolysis have worse clinical outcomes. 84, 85 Further investigation is required to phenotype VHA hypofibrinolysis to understand whether all patients with this entity are the same. In particular, what biomarker patterns are associated with VHA hypofibrinolysis, the mechanisms that drive low fibrinolytic activity, the temporal relationship with injury, shock and resuscitation, as well as clinical sequela, for example, mortality, venous thromboembolism (VTE), and organ failure. Improvements in the sensitivity of existing VHAs or development of diagnostic tools with greater definition to identify and characterize trauma patients with hyper-or hypofibrinolysis are urgently required.
Who Should Receive Antifibrinolytic Treatment?
Patients with TIC are eight times more likely to die within the first 24 hours 91 and more likely to require a massive transfusion, 45 with increased risk of multiorgan failure (MOF) and longer critical care and hospital stay. 91 Correct patient selection for treatment of hyperfibrinolysis provides an opportunity to improve upon these poor outcomes but given the lack of a validated diagnostic tool in trauma hemorrhage, the decision of who to treat requires an evidence-based clinical decision. The Clinical Randomization of an Antifibrinolytic in Significant Haemorrhage (CRASH)-2 trial randomized 20,211 injured patients to receive an antifibrinolytic or placebo based on pragmatic inclusion of all adult trauma patients who were bleeding or were suspected to be bleeding. 92 Patients who received empiric dosing of tranexamic acid (TXA) had a lower overall mortality (14.5 vs. 16%) and a lower risk of death due to bleeding (4.9 vs. 5.7%). Subgroup analysis from CRASH-2 found the greatest survival benefit to be in those patients with a systolic blood pressure less than 75 mm Hg, 92 and was confirmed in a single-center retrospective UK study, 93 which additionally reported reduced MOF in shocked patients who received TXA. Similarly, antifibrinolytic therapy administered empirically to military casualties with combat-associated traumatic hemorrhage was associated with lower inhospital mortality. 94 Once again, the greatest benefit was observed in patients requiring a massive transfusion with TXA independently associated with survival. Given the current lack of evidence regarding the diagnostic accuracy of VHA 71 and in the context of clinical trial data to support empiric antifibrinolytic therapy in suspected trauma hemorrhage, 92 withholding treatment for VHA confirmed hyperfibrinolysis cannot be recommended.
How Should Hyperfibrinolysis Be Treated?
The primary method of targeted reversal of hyperfibrinolysis in trauma is currently with the antifibrinolytic TXA. Important questions remain however over the optimal dosing regimen, timing, which patient subgroup derives most benefit and later thrombotic events. Early hemorrhage control and reversal of shock may in theory attenuate fibrinolytic activation through improved endothelial oxygenation and reduced tPA generation. Damage control resuscitation with a balanced transfusion strategy including early fresh frozen plasma 95 (a source of α2AP) and platelets may further dampen fibrinolytic activation 96 through increased PAI-1 delivery.
Evidence for the Use of Tranexamic Acid in Trauma
TXA (trans-4-aminomethylcyclohexane-1-carboxylic acid) is a synthetic analog of the amino acid lysine. It exerts an antifibrinolytic effect by competitively blocking the lysinebinding sites on plasminogen, thereby preventing the interaction of plasmin(ogen) with fibrin 97 and at higher concentrations is a noncompetitive inhibitor of plasmin. 98,99 First described over five decades ago, 99,100 TXA has found widespread global clinical application in part due to it being readily available, cheap, and having a proven safety profile. It is used routinely in the elective surgical setting, including gynecological, orthopedic, cardiac, and liver transplant surgery where it has been shown to reduce blood loss and the need for blood transfusion without increased thromboembolic events. 101, 102 TXA is considered a relatively old pharmacological agent although is currently being evaluated in international clinical trials of traumatic intracranial bleeding (CRASH-3), 103 nontraumatic gastrointestinal (Hemorrhage Alleviation with Tranexamic acid-Intestinal system), 104 and postpartum hemorrhage (World Maternal Antifibrinolytic Trial).
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The seminal study of TXA use in trauma hemorrhage (CRASH-2) was the first trial to demonstrate improved survival from bleeding with an antifibrinolytic. TXA was administered as a 1 g bolus over 10 minutes followed by a second 1 g infusion over 8 hours. The beneficial effects of early TXA therapy (bolus dose within 3 hours) in reducing all-cause mortality and death due to bleeding did not vary significantly by baseline risk of death.
106 TXA can therefore be administered safely to all patients with traumatic bleeding with no evidence to suggest it should be reserved only for high-risk patients with the most severe hemorrhage.
107
Performed in 40 countries, the CRASH-2 results did not identify any effect of geographical location on the efficacy of TXA on reducing death from bleeding. 108 In fact, countries with the most advanced health care systems appeared to derive the greatest relative risk reduction. Hemorrhage is the leading cause of preventable death globally from trauma and empiric use of TXA within 3 hours of injury, is likely to save many lives, 108 and be highly cost-effective.
109,110
TXA for the management of combat injury and hemorrhage was evaluated in the retrospective Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) 94 and MATTERs II studies. 111 In a study of 896 combat casualties, the MATTERs study concluded that patients receiving TXA (n ¼ 293) had a significantly lower overall inhospital mortality (17.4 vs. 23.9%). However, a potential confounding factor is that the TXA cohort received a greater volume of cryoprecipitate. To specifically address this, the MATTERs II study examined 1,332 patients to investigate the effect of TXA and cryoprecipitate on survival. Inhospital mortality was highest in patients who received neither TXA nor cryoprecipitate (23.6%) and was lowest in patients who received both TXA and cryoprecipitate (11.6%). The individual benefit of TXA and cryoprecipitate therapy was similar; both associated with an odds ratio (OR) of 0. 74, 114 recommend that empiric intravenous TXA be given to all trauma patients with active or suspected active hemorrhage as soon as possible and within 3 hours of injury. To achieve early administration, ideally within the first hour, it is recommended that procedures be in place for delivery of the first dose of TXA prehospital at the scene of injury.
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The survival benefit from antifibrinolytic therapy is greatest when it is administered early, within the first This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
hour following trauma. 115 Whether patients with confirmed (biomarker or VHA diagnosed) hyperfibrinolysis derive additional benefit is not known. Furthermore, the precise mechanism by which TXA confers survival benefit is unknown with some evidence to suggest it has anti-inflammatory action 93, 116, 117 in addition to its primary antifibrinolytic effects. As a result, the relative efficacy of TXA on early bleeding versus late deaths from MOF and sepsis is unclear. Paradoxically, late administration beyond 3 hours in the CRASH-2 trial was associated with increased risk of death due to bleeding. Possible explanations are that late delivery reflects poorer outcomes associated with delayed trauma care or is secondary to PAI-1-mediated suppression of fibrinolysis with resultant microvascular thromboses. 47 If hyperfibrinolysis transitions rapidly into a hypofibrinolytic state then further blockade of fibrinolysis with delayed antifibrinolytic therapy has the potential to be harmful although the effects of TXA, or other agents on hypofibrinolysis have yet to be characterized. Recently, a novel hypothesis based on data from a murine model of severe traumatic brain injury (TBI) has been proposed. 118 While both tPA and uPA levels in the brain increased following injury, they did so at different rates, with tPA peaking soon after TBI (within 3 hours) and uPA demonstrating a delayed peak after approximately 8 hours. TXA blocks tPA-mediated fibrinolysis, however, it actually enhances uPA-mediated fibrinolysis. 119 The delayed and protracted rise in uPA following injury combined with the ability of TXA to enhance uPA-mediated fibrinolysis provides a potential mechanism for the paradox of increased hemorrhage-related mortality with delayed therapy. Further research to evaluate the importance of uPA-mediated fibrinolysis in non-TBI-related trauma is required along with the potential role of therapeutics capable of attenuating both tPA and uPA in bleeding after major injury.
Alternative Antifibrinolytic Therapy in Trauma
The alternate antifibrinolytic agents aprotinin and epsilon aminocaproic acid (EACA) have some unfavorable properties compared with TXA, hence were not selected for clinical trial evaluation in trauma hemorrhage. Compared with TXA, the synthetic lysine analog EACA is 10 times less potent 120 and has not been shown to be associated with reduced transfusion requirements in elective surgery. 121 Aprotinin was withdrawn from the market after it was found to be associated with increased mortality in a randomized trial of patients undergoing cardiac surgery. 122 However, due to methodological deficiencies with this study, the conclusions were called into question and the European Medicines Agency have since lifted the suspension. 123 Aprotinin is a potent, long-acting antifibrinolytic and future clinical trials should be considered to determine the efficacy in trauma hemorrhage as well as any additional benefits over TXA. In the search for an ideal antifibrinolytic to treat hyperfibrinolysis, a greater understanding of the pathophysiology of fibrinolytic pathways in trauma is required to determine optimal pharmacodynamics and how best to monitor the effect of any drug on fibrinolytic activity.
Thrombotic Risk of Antifibrinolytic Therapy in Trauma
A principal concern with the use of antifibrinolytics is potentiation of a prothrombotic state, either immediately after trauma during increased thrombin generation or during the acute phase of recovery from major injury. Without thromboprophylaxis, multitrauma patients have a baseline risk of hospital-acquired VTE exceeding 50%, 124 with increasing age an important clinical predictor. 125 As trauma care advances, more patients survive beyond the initial 24 hours from injury, and consequently, more patients will be at risk of VTE. Some authors are concerned VTE rates are influenced directly by antifibrinolytic therapy 8 ; however, TXA has been shown to improve survival and is often administered to those at greatest risk of VTE (e.g., major trauma, shock, critical care utilization, and invasive procedures). In the surgical setting, a recent meta-analysis concluded that the risk of thromboembolic events with antifibrinolytic use was uncertain. 101 In a retrospective cohort study of 872,416 patients undergoing total hip or knee arthroplasty in the United States, antifibrinolytic therapy was associated with lower rates of blood transfusion without any increase in VTE. 126 CRASH-2 represents the largest randomized trial to evaluate antifibrinolytic use in trauma patients and found no increase in clinically significant vascular occlusive events with TXA compared with placebo (1.7 vs. 2.0%). In fact, patients who received TXA had a lower incidence of myocardial infarction postinjury. 92 While the MATTERs study reported higher unadjusted rates of VTE in patients receiving an antifibrinolytic (TXA vs. no TXA: PE, 2.7 vs. 0.3% and DVT, 2.4 vs. 0.2%), the difference was nonsignificant on multivariate analysis and the investigators attributed the difference to the higher injury burden and degree of shock in the TXA group.
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To reduce the incidence of VTE in this inherently high-risk group of patients, rather than avoiding early antifibrinolytic therapy, future research should focus on the role of proactive targeted thromboprophylaxis. Development of new methods to monitor fibrinolytic status as the trauma patient transitions from hyperfibrinolysis to a hypofibrinolytic state would permit earlier insertion of retrievable vena cava filters, or use of higher prophylactic doses of anticoagulants. In addition, the role of antiplatelet therapy in prevention of posttraumatic thrombotic events needs greater clarification.
Conclusion
Fibrinolytic activation within the limitations of current assays is presumed almost universal following trauma. Assessing hyperfibrinolysis through biomarker assays (e.g., PAP) remains the gold standard, and in comparison with VHA demonstrates the insensitivity of ROTEM and TEG for accurate diagnosis of increased fibrinolytic activation. Rapid evaluation of current or active fibrinolysis remains a challenge but while our understanding of available diagnostics improves, the decision whether to administer an antifibrinolytic agent should be based on available evidence from clinical trials. In line with current European guidelines, we recommend that all bleeding trauma patients (both suspected and confirmed), those that require immediate blood transfusion and all severely injured patients with evidence of hemorrhagic shock receive early empiric antifibrinolytic therapy.
Early empiric TXA is associated with a mortality benefit and is the current mainstay of treatment for hyperfibrinolysis in trauma. Which patient subgroups derive greatest benefit from reversal of hyperfibrinolysis, optimal timing, choice of drug, and potential for increased thrombotic events with antifibrinolytics should be the focus for future research. Given the advances in pharmaceutical engineering since TXA was first described over 50 years ago, it seems unlikely that such an old drug will remain the optimal agent to treat trauma patients. Improved understanding of the pathways that drive excessive fibrinolytic activation, including the role of uPA, may lead to the development of novel and more efficacious therapeutics. The fibrinolytic system is highly dynamic, evolving over time following injury and yet studies have on the whole been limited to measurement of fibrinolysis at the point of ED arrival. Future studies should focus on serial sampling to fully characterize the temporal changes that occur in the coagulation and fibrinolytic systems in response not just to the initial trauma, but over subsequent hours and days following resuscitation, surgery, and antifibrinolytic therapy. At present, TXA remains the most studied drug in traumatic hemorrhage, with sufficient evidence of efficacy and safety to recommend early empiric administration for the treatment of hyperfibrinolysis.
